Ella Jones, PhD

InstitutionUniversity of California San Francisco
Address2200 Post Street
San Francisco CA 94115
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of San FranciscoBS1987Chemistry
    University of California, DavisPhD1991Chemistry
    University of OxfordPost-doctoral training1993Chemistry
    Collapse Awards and Honors
    American Chemical Society1986Undergraduate Award in Analytical Chemistry
    American Chemical Society1987Student Award
    University of California, Davis1987  - 1991Non-resident Tuition Fellowship
    University of California, Davis1991Outstanding Graduate Student Nominee
    University of Oxford1991  - 1993Assoicated Member of Balliol College
    Mallinckrodt Medical, Inc.19942 Outstanding Patent Awards
    Monsanto Chemical Company1997  - 2001Chair of the Monsanto Technical Community, Phosphorus Chapter
    Solutia, Inc.2001Chair of the Solution Science and Engineering Network
    Department of Defense, Breast Cancer2009Peer Reviewer
    National Institute of Health, Challenge grants2009Peer Reviewer
    Department of Defense, Breast Cancer2010Peer Reviewer
    National Institute of Health, NIBIB Training SEP2010Peer Reviewer
    National Institute of Health, NIBIB Quantum Projects2010Peer Reviewer
    World Molecular Imaging Congress Meeting2013Section Chair and Moderator
    World Molecular Imaging Congress Meeting2013Poster Award Recipient
    Department of Defense, Breast Cancer2014Peer Reviewer
    New York State Department of Health2015Peer Reviewer
    Department of Defense, Breast Cancer2015Peer Reviewer
    Department of Defense, Breast Cancer2016Peer Reviewer

    Collapse Overview 
    Collapse Overview
    Dr. Ella Jones has over 12 years of research experience in the private sector pioneering the development of targeted molecules for cancer imaging. At UCSF, Dr. Jones integrated cell biology, protein engineering and synthetic chemistry to develop new reporter systems for in vivo imaging of disease biomarkers. She has been funded by NIH/NCI as a PI and has successfully produced various probes for preclinical and clinical use in optical and nuclear imaging. Her major contributions include the development of COX sensitive probe for breast cancer premalignancy and the prostate specific membrane antigen (PSMA) targeting probe for prostate cancer.

    More recently, Dr. Jones has taken a new career path focusing on translational breast cancer research. Her current research focuses on the evaluation of normal breast tissues quantified by MR imaging markers as potential independent breast cancer risk factors. Dr. Jones' vast experience in all modalities of imaging spans from the preclinical to the clinical space. In particular, her experience in PET and MR imaging well positions her to expand her research in the emerging field of hybrid PET/MRI for breast cancer characterization.

    Collapse Research 
    Collapse Research Activities and Funding
    Dedicated breast-PET and MRI for characterization of ER+ breast cancer
    Give Breast Cancer the Boot Oct 1, 2016 - Sep 30, 2018
    Role: PI
    Dedicated breast positron emission tomography at Mt. Zion
    Mount Zion Health Fund 2016Apr 1, 2016 - Mar 31, 2018
    Role: PI
    Characterizing the Evolution of Pre-malignant Tissues at High Risk for Malignancy
    NIH/NCI R01CA135626Sep 18, 2008 - Aug 31, 2011
    Role: Principal Investigator
    Molecular Beacons for Clinical Cancer Imaging
    NIH/NCI R44CA094427May 15, 2002 - Jun 30, 2005
    Role: Co-Principal Investigator
    Molecular Beacons for Clinical Cancer Imaging
    NIH/NCI R43CA094427May 15, 2002 - Nov 14, 2002
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Press RH, Shu HG, Shim H, Mountz JM, Kurland BF, Wahl RL, Jones E, Hylton NM, Gerstner ER, Nordstrom RJ, Henderson L, Kurdziel KA, Vikram B, Jacobs MA, Holdhoff M, Taylor E, Jaffray DA, Schwartz LH, Mankoff DA, Kinahan PE, Linden HM, Lambin P, Dilling TJ, Rubin DL, Hadjiiski L, Buatti JM. The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective. Int J Radiat Oncol Biol Phys. 2018 Jun 29. PMID: 29966725.
      View in: PubMed
    2. Olshen A, Wolf D, Jones E, Newitt D, van ‘t Veer LJ, Yau C, Esserman L, Wulfkuhle JD, Gallagher RI, Singer L, Petricoin EF, Hylton N, Park CC. Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham). 2018 01; 5(1):011014. PMID: 29296631.
      View in: PubMed
    3. Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones E, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Breast Cancer Res. 2017 Sep 11; 19(1):107. PMID: 28893315.
      View in: PubMed
    4. Jones E, Ray KM, Li W, Seo Y, Franc BL, Chien AJ, Esserman LJ, Pampaloni MH, Joe BN, Hylton NM. Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer. Clin Breast Cancer. 2017 06; 17(3):e155-e159. PMID: 28110902.
      View in: PubMed
    5. Li W, Arasu V, Newitt DC, Jones E, Wilmes L, Gibbs J, Kornak J, Joe BN, Esserman LJ, Hylton NM. Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL. Tomography. 2016 Dec; 2(4):378-387. PMID: 28066808.
      View in: PubMed
    6. Kurland BF, Aggarwal S, Yankeelov TE, Gerstner ER, Mountz JM, Linden HM, Jones E, Bodeker KL, Buatti JM. Accrual Patterns for Clinical Studies Involving Quantitative Imaging: Results of an NCI Quantitative Imaging Network (QIN) Survey. Tomography. 2016 Dec; 2(4):276-282. PMID: 28127586.
      View in: PubMed
    7. Dannoon S, Ganguly T, Cahaya H, Geruntho JJ, Galliher MS, Beyer SK, Choy CJ, Hopkins MR, Regan M, Blecha JE, Skultetyova L, Drake CR, Jivan S, Barinka C, Jones E, Berkman CE, VanBrocklin HF. Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer. J Med Chem. 2016 06 23; 59(12):5684-94. PMID: 27228467.
      View in: PubMed
    8. Keenan KE, Peskin AP, Wilmes LJ, Aliu SO, Jones E, Li W, Kornak J, Newitt DC, Hylton NM. Variability and bias assessment in breast ADC measurement across multiple systems. J Magn Reson Imaging. 2016 Oct; 44(4):846-55. PMID: 27008431.
      View in: PubMed
    9. Keenan KE, Wilmes LJ, Aliu SO, Newitt DC, Jones E, Boss MA, Stupic KF, Russek SE, Hylton NM. Design of a breast phantom for quantitative MRI. J Magn Reson Imaging. 2016 Sep; 44(3):610-9. PMID: 26949897; PMCID: PMC4983524 [Available on 09/01/17].
    10. Lo WC, Li W, Jones E, Newitt DC, Kornak J, Wilmes LJ, Esserman LJ, Hylton NM. Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes. PLoS One. 2016; 11(2):e0142047. PMID: 26886725; PMCID: PMC4757528.
    11. Keenan KE, Peskin AP, Wilmes LJ, Aliu SO, Jones E, Li W, Kornak J, Newitt DC, Hylton NM.Variability and Bias Assessment in Breast ADC Measurement Across Multiple Systems. JMRI. 2016; (in press).
    12. Keenan KE, Aliu SO, Wilmes LJ, Newitt DC, Jones E, Li W, Boss MA, Stupic KF, Russek SE, Hylton NM.Design of a Breast Phantom for Quantitative Magnetic Resonance Imaging. JMRI. 2016; (in press).
    13. Drake CR, Estévez-Salmerón L, Gascard P, Shen Y, Tlsty TD, Jones E. Towards aspirin-inspired self-immolating molecules which target the cyclooxygenases. Org Biomol Chem. 2015 Dec 07; 13(45):11078-86. PMID: 26400105; PMCID: PMC4644089 [Available on 12/07/16].
    14. Aliu SO, Jones E, Azziz A, Kornak J, Wilmes LJ, Newitt DC, Suzuki SA, Klifa C, Gibbs J, Proctor EC, Joe BN, Hylton NM. Repeatability of quantitative MRI measurements in normal breast tissue. Transl Oncol. 2014 Feb; 7(1):130-7. PMID: 24772216; PMCID: PMC3998684.
    15. McLaughlin RL, Newitt DC, Wilmes LJ, Jones E, Wisner DJ, Kornak J, Proctor E, Joe BN, Hylton NM. High resolution in vivo characterization of apparent diffusion coefficient at the tumor-stromal boundary of breast carcinomas: a pilot study to assess treatment response using proximity-dependent diffusion-weighted imaging. J Magn Reson Imaging. 2014 May; 39(5):1308-13. PMID: 24719242; PMCID: PMC3983569.
    16. Jones E, Sinha SP, Newitt DC, Klifa C, Kornak J, Park CC, Hylton NM. MRI enhancement in stromal tissue surrounding breast tumors: association with recurrence free survival following neoadjuvant chemotherapy. PLoS One. 2013; 8(5):e61969. PMID: 23667451; PMCID: PMC3646993.
    17. Wilmes LJ, McLaughlin RL, Newitt DC, Singer L, Sinha SP, Proctor E, Wisner DJ, Saritas EU, Kornak J, Shankaranarayanan A, Banerjee S, Jones E, Joe BN, Hylton NM. High-resolution diffusion-weighted imaging for monitoring breast cancer treatment response. Acad Radiol. 2013 May; 20(5):581-9. PMID: 23570936.
      View in: PubMed
    18. Mongan J, Rathnayake S, Fu Y, Wang R, Jones E, Gao DW, Yeh BM. In vivo differentiation of complementary contrast media at dual-energy CT. Radiology. 2012 Oct; 265(1):267-72. PMID: 22778447; PMCID: PMC3447173.
    19. Tucker RM, Parcher BW, Jones E, Desai TA. Single-injection HPLC method for rapid analysis of a combination drug delivery system. AAPS PharmSciTech. 2012 Jun; 13(2):605-10. PMID: 22535518; PMCID: PMC3364377.
    20. Jones E, Schooler J, Miller DC, Drake CR, Wahnishe H, Siddiqui S, Li X, Majumdar S. Characterization of human osteoarthritic cartilage using optical and magnetic resonance imaging. Mol Imaging Biol. 2012 Feb; 14(1):32-9. PMID: 21384207; PMCID: PMC3258397.
    21. Davison HR, Taylor S, Drake C, Phuan PW, Derichs N, Yao C, Jones E, Sutcliffe J, Verkman AS, Kurth MJ. Functional fluorescently labeled bithiazole ?F508-CFTR corrector imaged in whole body slices in mice. Bioconjug Chem. 2011 Dec 21; 22(12):2593-9. PMID: 22034937; PMCID: PMC3245868.
    22. Drake CR, Miller DC, Jones E. Activatable Optical Probes for the Detection of Enzymes. Curr Org Synth. 2011 Aug; 8(4):498-520. PMID: 23519774.
      View in: PubMed
    23. Cattaruzza F, Lyo V, Jones E, Pham D, Hawkins J, Kirkwood K, Valdez-Morales E, Ibeakanma C, Vanner SJ, Bogyo M, Bunnett NW. Cathepsin S is activated during colitis and causes visceral hyperalgesia by a PAR2-dependent mechanism in mice. Gastroenterology. 2011 Nov; 141(5):1864-74.e1-3. PMID: 21802389; PMCID: PMC4041343.
    24. Drake CR, Miller D and Jones EF.Activatable Optical Probes for the Detection of Enzymes. Current Organic Synthesis. 2011; 8(4):498-520.
    25. Noey, S.; Tam., S.; Pham, D. M.; Curtis, J.; Jones, E.F. .Tungsten Cluster Synthesis and Subsequent Ligand-Exchange Reactions. J. Chem. Ed. 2011; 88(6):793-797.
    26. Meier R, Krug C, Golovko D, Boddington S, Piontek G, Rudelius M, Sutton EJ, Baur-Melnyk A, Jones E, Daldrup-Link HE. Indocyanine green-enhanced imaging of antigen-induced arthritis with an integrated optical imaging/radiography system. Arthritis Rheum. 2010 Aug; 62(8):2322-7. PMID: 20506388; PMCID: PMC2921028.
    27. Lapi SE, Wahnishe H, Pham D, Wu LY, Nedrow-Byers JR, Liu T, Vejdani K, VanBrocklin HF, Berkman CE, Jones E. Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. J Nucl Med. 2009 Dec; 50(12):2042-8. PMID: 19910433; PMCID: PMC3575752.
    28. Watkins GA, Jones E, Scott Shell M, VanBrocklin HF, Pan MH, Hanrahan SM, Feng JJ, He J, Sounni NE, Dill KA, Contag CH, Coussens LM, Franc BL. Development of an optimized activatable MMP-14 targeted SPECT imaging probe. Bioorg Med Chem. 2009 Jan 15; 17(2):653-9. PMID: 19109023; PMCID: PMC2639212.
    29. Boddington S, Sutton EJ, Jones E, Purcell DD, Henning TD, Tavri S, Meier R, Sista A, Fu Y, Daldrup-Link H. Improved fluorescence of indocyanine green in vitro and in vivo after simple cooling procedures. Contrast Media Mol Imaging. 2008 Sep-Oct; 3(5):191-7. PMID: 18973215.
      View in: PubMed
    30. He J, VanBrocklin HF, Franc BL, Seo Y, Jones E. Nanoprobes for Medical Diagnosis and Management: Current Status of Nanotechnology in Molecular Imaging. Current NanoScience. 2008; 4(1):17-29.
    31. Gao Q, Reynolds GE, Innes L, Pedram M, Jones E, Junabi M, Gao DW, Ricoul M, Sabatier L, Van Brocklin H, Franc BL, Murnane JP. Telomeric transgenes are silenced in adult mouse tissues and embryo fibroblasts but are expressed in embryonic stem cells. Stem Cells. 2007 Dec; 25(12):3085-92. PMID: 17823235.
      View in: PubMed
    32. Fung EY, Olmstead MM, Vickery JC, Balch AL .Glowing gold rings: Solvoluminescence from Planar Trigold(I) Complexes. Coord. Chem. Rev. 1998; 171:151.
    33. Vickery JC, Olmstead MM, Fung EY, Balch AL.Solvent-Stimulated Luminescence from the Supramolecular Aggregation of a Trinuclear Gold(I) Complex that Displays Extensive Intermolecular Au…Au Interactions. Angew. Chem., Int. Ed. Engl. 1997; 36:1179.
    34. Lau KW, Hu NM, Yen MH, Fung EY, Grzybicki S, Matamoros R, Curtis JC .Solvent, Electrolyte and Solute Shape Effects on Optical Electron Transfer in Mixed-Valence Ruthenium Ammine Dimers. Inorg. Chim. Acta. 1994; 226:137.
    35. Salaymeh F, Berhane S, Yusof R, de la Rosa R, Fung EY, Matamoros R, Lau KW, Zheng Q, Kober EM, Curtis JC .Electronic Coupling in Mixed-Valence Binuclear Ruthenium Ammine Complexes as Probed by an Electrochemical Method and an Extension of R. S. Mulliken's Theory of Donor-Acceptor Interactions. Inorg. Chem. 1993; 32:3895.
    36. Balch AL, Davis BJ, Fung EY, Olmstead MM .Palladium-thallium Interactions in Dinuclear Complexes with Structural Components that Place the Two Metal Centers in Close Proximity. Inorg. Chim. Acta. 1993; 212:149.
    37. Balch AL, Fung EY, Nagle JK, Olmstead MM, Rowley SP .Lead(II)/Platinum(II) Complexes with and without Pb-Pt Interactions. Inorg. Chem. 1993; 32:3295.
    38. Balch AL, Fung EY .Two- and Four-Coordinate Gold(I) Complexes of Tris(2-diphenylphosphinoethyl)phosphine. Inorg. Chem. 1990; 29:4764.
    39. Balch AL, Fung EY, Olmstead MM .Preparation and Structure of Two Polynuclear Aggregate Obtained Using the Metalloligand {ClAuPPh2CH2}2AsPh. Inorg. Chem. 1990; 29:3203.
    40. Balch AL, Fung EY, Olmstead MM .Polynuclear ((Diphenylphosphino)-methyl)-phenylarsine Bridged Complexes of Gold(I). Bent Chains of Gold(I) and a Role for Au(I)-Au(I) Interactions in Guiding a Reaction. J. Am. Chem. Soc. 1990; 112:5181.
    41. Fung EY, Chua A, Curtis JC .Evidence for a Specific Solvent-Solute Interaction as a Major Contributor to the Excited-State Distortion of the Emitting Charge-Transfer State in the Complex (bpy)2RuII(CN)2. Inorg. Chem. 1988; 27:1294.
    42. Chang JP, Fung EY, Curtis JC .Evidence for Specific Solvent-Solute Interactions as a Major Contributor to the Franck-Condon Energy in Intervalence-Transfer Absorptions of Ruthenium Amine Complexes. Inorg. Chem. 1986; 25:4233.
    Ella's Networks
    Derived automatically from this person's publications.
    People in Profiles who have published with this person.
    Related Authors
    People who share related concepts with this person.